nach oben

International Journal of Clinical Oncology

Erschienen in:

31.10.2017 | Original Article

Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma

verfasst von: Hiroshi Kobayashi, Tomotake Okuma, Hiroyuki Oka, Toshihide Hirai, Takahiro Ohki, Masachika Ikegami, Ryoko Sawada, Yusuke Shinoda, Toru Akiyama, Kenji Sato, Satoshi Abe, Hirotaka Kawano, Takahiro Goto, Sakae Tanaka

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Pazopanib is a multi-tyrosine kinase inhibitor that is used to treat advanced soft-tissue sarcoma, and its efficacy has been confirmed in several clinical trials, although no clinically useful biomarkers have been identified. In other cancers, the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and the lymphocyte-to-monocyte ratio (LMR) are associated with chemotherapy response and prognosis. Therefore, we aimed to evaluate the associations of pazopanib response with NLR, PLR, and LMR among patients with advanced soft-tissue sarcoma.

Methods

Data regarding NLR, PLR, and LMR were obtained for 25 patients who received pazopanib for soft-tissue sarcoma. The patients were categorized according to their values for NLR (≥3.8 vs. <3.8), PLR (≥230 vs. <230), and LMR (≥2.4 vs. <2.4), and we evaluated the associations of these markers with progression-free survival and overall survival using Kaplan–Meier curves and Cox proportional models.

Results

No significant differences in progression-free survival or overall survival were observed based on the pre-treatment NLR, PLR, and LMR values. However, decreased NLR values after treatment using pazopanib were independently associated with significantly prolonged progression-free survival (hazard ratio: 0.07, p = 0.001) and overall survival (hazard ratio: 0.17, p = 0.0006).

Conclusions

Decreased NLR values after treatment using pazopanib may predict high efficacy and favorable outcomes among patients with advanced soft-tissue sarcoma.

Nur mit Berechtigung zugänglich

Clark MA, Fisher C, Judson I et al (2005) Soft-tissue sarcomas in adults. N Engl J Med 353:701–711CrossRefPubMed

Byerly S, Chopra S, Nassif NA et al (2016) The role of margins in extremity soft tissue sarcoma. J Surg Oncol 113:333–338CrossRefPubMed

Callegaro D, Miceli R, Bonvalot S et al (2016) Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol 17:671–680CrossRefPubMed

van der Graaf WT, Blay JY, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879–1886CrossRefPubMed

Schöffski P, Chawla S, Maki RG et al (2016) Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387:1629–1637CrossRefPubMed

Kawai A, Araki N, Sugiura H et al (2015) Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol 16:406–416CrossRefPubMed

Demetri GD, Chawla SP, von Mehren M et al (2009) Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 27:4188–4196CrossRefPubMed

Koehler K, Liebner D, Chen JL (2016) TP53 mutational status is predictive of pazopanib response in advanced sarcomas. Ann Oncol 27:539–543CrossRefPubMed

Palma N, Morris JC, Ali SM et al (2015) Exceptional response to pazopanib in a patient with urothelial carcinoma harboring FGFR3 activating mutation and amplification. Eur Urol 68:168–170CrossRefPubMed

10.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674CrossRefPubMed

11.

McMillan DC (2009) Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12:223–226CrossRefPubMed

12.

Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570CrossRefPubMed

13.

Qi Q, Zhuang L, Shen Y et al (2016) A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer 122:2158–2167CrossRefPubMed

14.

Wang F, Liu ZY, Xia YY et al (2015) Changes in neutrophil/lymphocyte and platelet/lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer. Oncol Lett 10:3411–3418CrossRefPubMedPubMedCentral

15.

Asano Y, Kashiwagi S, Onoda N et al (2016) Predictive value of neutrophil/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer. Br J Cancer 114:14–20CrossRefPubMedPubMedCentral

16.

Ni XJ, Zhang XL, Ou-Yang QW et al (2014) An elevated peripheral blood lymphocyte-to-monocyte ratio predicts favorable response and prognosis in locally advanced breast cancer following neoadjuvant chemotherapy. PLoS One 9:e111886CrossRefPubMedPubMedCentral

17.

Jiang L, Jiang S, Situ D et al (2015) Prognostic value of monocyte and neutrophils to lymphocytes ratio in patients with metastatic soft tissue sarcoma. Oncotarget 6:9542–9550PubMedPubMedCentral

18.

Szkandera J, Gerger A, Liegl-Atzwanger B et al (2015) The derived neutrophil/lymphocyte ratio predicts poor clinical outcome in soft tissue sarcoma patients. Am J Surg 210:111–116CrossRefPubMed

19.

Que Y, Qiu H, Li Y et al (2015) Preoperative platelet-lymphocyte ratio is superior to neutrophil-lymphocyte ratio as a prognostic factor for soft-tissue sarcoma. BMC Cancer 15:648CrossRefPubMedPubMedCentral

20.

Kobayashi N, Usui S, Kikuchi S et al (2012) Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer. Lung Cancer 75:223–227CrossRefPubMed

21.

Milne K, Alexander C, Webb JR et al (2012) Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. J Transl Med 10:33CrossRefPubMedPubMedCentral

22.

Kusumanto YH, Dam WA, Hospers GA et al (2003) Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 6:283–287CrossRefPubMed

23.

Nagaraj S, Schrum AG, Cho HI et al (2010) Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 15:3106–3116CrossRef

24.

Kobayashi M, Kubo T, Komatsu K et al (2013) Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy. Med Oncol 30:556CrossRefPubMed

25.

Terme M, Pernot S, Marcheteau E et al (2013) VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 73:539–549CrossRefPubMed

26.

Sharpe K, Stewart GD, Mackay A et al (2013) The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clin Cancer Res 19:6924–6934CrossRefPubMed

27.

Pal SK, Hossain DM, Zhang Q et al (2015) Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile. J Urol 193:1114–1121CrossRefPubMed

28.

Gasic GJ, Gasic TB, Stewart CC (1968) Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 61:46–52CrossRefPubMedPubMedCentral

29.

Nieswandt B, Hafner M, Echtenacher B et al (1999) Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 59:1295–1300PubMed

30.

Labelle M, Begum S, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20:576–590CrossRefPubMedPubMedCentral

31.

Yoshizawa K, Okamoto T, Moriya K et al (1994) Effects of natural human interleukin-6 on thrombopoiesis and tumor progression in tumor-bearing mice. Cancer Lett 79:83–89CrossRefPubMed

32.

Nakamura T, Matsumine A, Kawai A et al (2016) The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer 122:1408–1416CrossRefPubMedPubMedCentral

Titel: Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma
verfasst von: Hiroshi Kobayashi
Tomotake Okuma
Hiroyuki Oka
Toshihide Hirai
Takahiro Ohki
Masachika Ikegami
Ryoko Sawada
Yusuke Shinoda
Toru Akiyama
Kenji Sato
Satoshi Abe
Hirotaka Kawano
Takahiro Goto
Sakae Tanaka
Publikationsdatum: 31.10.2017
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 2/2018
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-017-1199-6

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

Selecting patients for hyperthermia combined with preoperative chemoradiotherapy for locally advanced rectal cancer

Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer

Repeat cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal carcinomatosis of appendiceal origin

Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors

A survival analysis using physique-adjusted tumor size of non-small cell lung cancer

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie